(Peer-Reviewed) Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
Jingya Guo 郭静雅 ¹ ², Yong Liang 梁永 ³, Diyuan Xue 薛娣媛 ¹ ², Jiao Shen ¹ ², Yueqi Cai ¹ ², Jiankun Zhu ³, Yang-Xin Fu 傅阳心 ³, Hua Peng 彭华 ¹
¹ Chinese Academy of Sciences Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China 中国科学院 生物物理研究所 感染与免疫重点实验室
² University of Chinese Academy of Sciences, Beijing, China 中国科学院大学
³ Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Cell Research, 2021-08-10
Abstract
IL-15 is a promising cytokine to expand NK and CD8⁺ T cells for cancer immunotherapy, but its application is limited by dose-limiting, on-target off-tumor toxicity.
Here, we have developed a next-generation IL-15 that is activated inside the tumor microenvironment (TME). This pro-IL-15 has the extracellular domain of IL-15Rβ fused to the N-terminus of sIL-15-Fc through a tumor-enriched Matrix Metalloproteinase (MMP) cleavable peptide linker to block its activity. Unlike sIL-15-Fc, pro-IL-15 does not activate the peripheral expansion of NK cells and T cells, thus reducing systemic toxicity, but it still preserves efficient anti-tumor abilities.
In various mouse tumors, the anti-tumor effect of pro-IL-15 depends on intratumoral CD8⁺ T cells and IFN-γ. Pro-IL-15 increases the stem-like TCF1⁺Tim-3⁻CD8⁺ T cells within tumor tissue and helps overcome immune checkpoint blockade (ICB) resistance. Moreover, pro-IL-15 synergizes with current tyrosine kinase inhibitor (TKI) targeted-therapy in a poorly inflamed TUBO tumor model, suggesting that pro-IL-15 helps overcome targeted-therapy resistance.
Our results demonstrate a next-generation IL-15 cytokine that can stimulate potent anti-tumor activity without severe toxicity.
Multiplexed stimulated emission depletion nanoscopy (mSTED) for 5-color live-cell long-term imaging of organelle interactome
Yuran Huang, Zhimin Zhang, Wenli Tao, Yunfei Wei, Liang Xu, Wenwen Gong, Jiaqiang Zhou, Liangcai Cao, Yong Liu, Yubing Han, Cuifang Kuang, Xu Liu
Opto-Electronic Advances
2024-07-05
